The pathway-based microarray classification approach leads to a new era of genomic research. However, this approach is limited by the issues in quality of pathway data. Usually the pathway data are curated from biological literatures and in specific biological experiment (e.g., lung cancer experiment), context free pathway information collection process takes place leading to the presence of uninformative genes in the pathways. Many methods in this approach neglect these limitations by treating all genes in a pathway as significant. In this paper, we proposed a hybrid of support vector machine and smoothly clipped absolute deviation with group-specific tuning parameters (gSVM-SCAD) to select informative genes within pathways before the pathway evaluation process. Our experiment on canine, gender and lung cancer datasets shows that gSVM-SCAD obtains significant results in identifying significant genes and pathways and in classification accuracy.
Introduction
Incorporation of prior pathway data into microarray analysis has become a popular research area in bioinformatics due to the advantages in providing the further biological interpretation compare to single gene microarray analysis. These advantages have triggered various experiments and approaches in order to identify informative genes and pathways that contribute to the certain cellular processes. The goal of the pathway-based microarray analysis is to identify pathways and also genes within pathways that contribute to the phenotypes of interests. This is in contrast to single gene microarray analysis that identifies only the significant genes. Two most common approaches in pathway-based microarray analysis are Enrichment Analysis approaches (EA) and Machine Learning approaches (ML) .
However, there are some challenges in pathway-based microarray analysis such as the quality of pathway data where some of the uninformative genes may be included into pathways while informative genes being excluded . Furthermore, another concern is that pathway data are usually curated from the biological context free experiment; it can be that only several genes take part in the certain cellular process when it goes to the phenotype specific analysis (e.g., lung cancer research). In order to deal with the challenges in improving quality of pathway data, several researchers attempt to refining the pathway data to specific conditions by removing the unaltered genes in the pathways and including the additional information of the functional interpretation of the pathways or gene groups (Hummel et al., 2008) in EA approaches. While for ML approaches, several researchers includes the gene selection method to select the informative genes within a pathway before the classification model building instead of including all the genes within a pathway into the model building (Tai and Pan, 2007a; Tai and Pan, 2007b; Chen et al., 2008) .
However, there are some limitations in EA approaches where these approaches considered all the genes within pathways are equally important ) and the goal is to identify the significant pathways (He and Yu, 2010) . Alternatively, ML can select the only important genes within a pathway by including the gene selection method. In contrast to EA, the ML goal is to identify both relevant genes and pathways that related to the phenotypes of interests. Therefore, ML can bring more insight in gaining and understanding further biological knowledge. ML is used in this research due to its advantages. However, there are some arguments against incorporating gene selection methods in ML where the informative genes may be discarded . This is due to the nature of microarray data which has large number of coefficients, it can impose sparseness and biasness on the penalty function that act as the gene selection method in evaluating the informative genes (Fan and Li, 2001) . Therefore, the efficient and robust gene selection technique is needed in order to deal effectively with the problems arises in pathway-based microarray analysis.
Following the good results obtained from the application of Support Vector Machines (SVM) in classifying gene expression data from previous researches, Zhang et al. (2006) had embedded SVM with Smoothly Clipped Absolute Deviation (SCAD) penalty and produced the SVM-SCAD. With the SCAD as a penalty function (Fan and Li, 2001) , it provides nearly unbiased coefficient estimation and select the important genes consistently compared to other popular penalty function such as Least Absolute Shrinkage and Selection Operator (LASSO) by (Tibshirani, 1996) . In the research from Zhang et al. (2006) , SVM-SCAD had proved its ability in selecting the informative genes and the method is comparable to LASSO penalty function. Hence, in order to identify both the significant genes and pathways that related to phenotypes of interests, this paper proposed an improved of SVM-SCAD with group-specific tuning parameters. Our proposed method termed as gSVM-SCAD.
Description of SVM-SCAD and the proposed method (gSVM-SCAD)

SVM-SCAD
Given a dataset {(x i , y i )}, y i  {-1, 1} is the sample tissue with possible two classes y i = -1 and y i = 1 for each dataset used in this paper, while x i = (x i1 ,…,x id ) R d represents the input vector of expression levels of d genes of the i-th sample tissue. SVM is a large margin classifier which separates classes of interest by maximising the margin between them using the kernel function (Wang and Wu, 2006; Zhang et al., 2006; Wang et al., 2007) . This has been widely used especially in microarray classification area (Guyon et al., 2002) . SVM distinguish input variables into its classes by a margin of
[1 -y i f(x i )] + is the SVM convex hinge loss function where
while pen λ (β) is the penalty function with parameters λ, where β = (β 1 ,…,β i ) are the coefficients of the hyperplane, while c is the intercept of the hyperplane. Hinge loss function is a commonly used loss function in SVM in order to keep the fidelity of the resulting model to the dataset (Wang and Wu, 2006) . Even though SVM has proven its superior ability in classifying high dimensional data, the standard SVM can suffer from irrelevant data, since all the variables are used for constructing the classifier (Zhang et al., 2006) . This is due to the usage of the L 2 penalty in a soft-thresholding function for the common SVM. The detailed applications of L 2 penalty in a soft-thresholding function and its drawbacks in identifying noises can be obtained from (Zhang et al., 2006) . A penalty function is usually used as a variable selection in the statistics and in bioinformatics it is called as gene selection. SCAD is different from other popular penalty functions such as LASSO, also called the L 1 penalty (Tibshirani, 1996) , this is because SCAD provides nearly unbiased coefficient estimation when dealing with large coefficients. This is contrary to other penalty functions that usually increase the penalty linearly as the coefficient increases (Fan and Li, 2001) . SCAD penalty has the form of
where P λ (β j ) is a penalty function with tuning parameter λ for β j . For providing nearly unbiased, sparsity and continuity estimate of β (Zhang et al., 2006) , the continuous differentiable penalty function is defined as:
where a and λ are tuning parameters with a > 2 and λ > 0 (Fan and Li, 2001) . For a tuning parameter a, Fan and Li (2001) suggested the parameter a = 3.7 due to the minimal achievement in a Bayes risk. Therefore, in this research a = 3.7 is used while λ is a tuning parameter obtained using General Approximate Cross Validation (GACV) tuning parameter selection methods (as discussed latter).
In order to surmount the limitations of the SVM due to its inability to distinguish between noise and informative data, Zhang et al. (2006) proposed the SVM-SCAD by replacing the L 2 penalty in function (1) with (2), which takes the form
and thus the SVM-SCAD can simultaneously provide gene selection and classification. In order to select the informative genes, SVM-SCAD have to minimise the function (3) using the Successive Quadratic Algorithm (SQA) and repeated for k-th times until convergence. During the procedure, if k j  , the gene is considered as uninformative.
Where  is the coefficient for the gene j in the k-th iteration and  is a pre-selected small positive thresholding value with  = y i -f(x i )
Tuning parameter selection method
In SCAD there are two tuning parameters namely a and  that play an important role in determining an effective predictive model. The tuning parameter selection in SVM-SCAD is only used to estimate the nearly optimal  in order to identify the effective predictive model for SCAD. In this paper, the GACV by Wahba et al. (2000) is used in order to select the nearly optimal . The formula on calculating the GACV as given in following equation.
where n is a total number of samples, DF  is a degree of freedom where
Space (RKHS) with SVM reproducing kernel K (see Lin et al., 1998; Wahba, 1999) for further explanations on RKHS). If all samples in microarray data are correctly classified, then y i f(x i ) > 0 and sum following (2) in DF  does not appear and
where  is the hard margin of an SVM (Wahba et al., 2000) . The nearly optimal tuning parameter  is obtained by minimising the error rate from the GACV.
The proposed method (gSVM-SCAD)
In SVM-SCAD, the magnitude of penalisation of  is determined by two tuning parameters a and . Since a has been setup as 3.7 (Fan and Li, 2001) , there is only one parameter  left that play an important role. In order to incorporate pathway or set of gene data, the gSVM-SCAD used group-specific parameters  j estimation, using the framework proposed by Pan (2007a, 2007b) . In this paper, there are k groups of genes where k = 1,,n, each gene able to be in one or more pathways. We grouped the genes based on their pathway information from the pathway data. In order to provide the group-specific tuning parameters, we modified (2) to the form of
where by allowing each pathway to have its own parameter λ k as in (5) instead of general λ in (2), the genes within pathways can be selected and classified more accurately. Figure 1 illustrates the procedure of gSVM-SCAD. The procedure consisted of three main steps. In step 1, the genes in microarray data are selected and grouped based on their prior pathway information from the pathway data. This process repeated for each pathway in the pathway data and there is a possibility that some genes are not involved in any pathways. From this step, the new sets of gene expression data are produced to be evaluated by the SVM-SCAD. For j=1 to max number of pathways in PD do Find genes from GE that related to the pathway Select and assign the related genes as a one group End-for Step 2: Evaluate the pathways For j=1 to max number of pathways in PD do
Step 2.1: Estimation of TP using a GACV For TP = 0.001 to 0.009 ,0.01 to 0.09 and TP = 0.1 to 1 do
Step 2.2: Select the informative genes using the SVM-SCAD Let β k as the estimate of β at step k where k = 0, … , n The value of β 0 set by an SVM While β k not converge do
The gene j considered as non-informative and discarded End-if End-while Step 2.3: Classify the selected genes using an SVM
Step 3: Calculate the classification error using a 10-fold CV
End-for End
In step 2, each pathway is evaluated using the SVM-SCAD. This procedure is started with the tuning parameter selection (step 2.1) where in this research the grid search ranges from 0.001 to 0.001, 0.01 to 0.09 and 0.1 to 1 are used. The GACV is used to estimate the error for each tuning parameter value from the grid search. The nearly optimal tuning parameter produces the minimum GACV error. In step 2.2, the genes in the pathway are evaluated using SVM-SCAD and the informative genes within pathway is selected and selected while the non-informative genes are excluded from the pathway. In step 2.3, the informative genes obtained are classified between phenotypes of interests using an SVM. The classification error from the selected genes for each pathway is calculated using tenfold CV in step 3. Biological validation for top pathways is conducted using the information from the biological research databases.
There are several main differences between gSVM-SCAD and other current methods in ML approaches. Firstly, it provides the genes selection method to identify and select the informative genes that are related to the pathway and the phenotype of interest. Secondly, the penalty function SCAD is more robust when dealing with a high number of genes and it selects important genes more consistently than other popular LASSO (L 1 ) penalty function (Wang et al., 2007) . And lastly, with group-specific tuning parameters, the gSVM-SCAD provides more flexibility in choosing the best  for each pathway.
Therefore, by selecting the informative genes within pathway, the gSVM-SCAD can be seen as the best method in dealing with pathway data quality problems in pathway-based microarray analysis.
Experimental datasets
The performance of the gSVM-SCAD is tested using two types of data, gene expression and biological pathway data. The role of biological pathway data is as a metadata or prior biological knowledge. Both gene expression and pathway data are the same as those used by Pang et al. (2006) research. Both data can be downloaded at http://bioinformatics. med.yale.edu/pathway-analysis/datasets.htm.
Gene expression datasets
In gene expression data, it consists of m samples and n gene expression levels. The first column of the data represents the name of genes while the next column represents the gene expression levels. The dataset forming a matrix of E ={e i, j } mxn where e i, j represents the expression level of the gene j in the tissue sample i. In this paper, three gene expression datasets are used: lung cancer, canine and gender. The information of the datasets is shown in Table 1 . 
Biological pathway data
Total 480 pathways are used in this research. 168 pathways were taken from KEGG and 312 pathways were taken Biocarta pathway database. In a pathway dataset, the first column represents the pathway name while the second column represents the gene name.
Experimental results and discussion
In this paper, to evaluate the performance of the gSVM-SCAD, we used a tenfold cross validation (tenfold CV) classification accuracy. The results obtained from the gSVM-SCAD are validated with the biological literatures and databases. Since the limited pages for this paper, we only chose the top five pathways with highest tenfold CV accuracy from all three datasets for biological validation (commonly applied with several authors such as Pang et al. (2006) and Wang et al. (2008) ).
Performance evaluation
For the performance evaluation of the SCAD penalty function, the SCAD was compared with the popular L 1 penalty function by hybridising it with an SVM classifier (L 1 SVM), obtained from R package penalised SVM (Becker et al., 2009 ). The L 1 SVM also applied with group-specific tuning parameters to determine λ. This experiment was done intentionally to test the robustness of the SCAD penalty in identifying informative genes when dealing with large coefficients compare to the L 1 method. Then, the gSVM-SCAD was compared with the current SVM-SCAD with respect to one general parameter tuning for all pathways, the tuning parameter λ = 0.4 as used by Zhang et al. (2006) . For comparison with other classification methods without any gene selection process, the gSVM-SCAD was compared with four classifiers that are without any penalty function or gene selection method. The classifiers are PathwayRF (Pang et al., 2006) , neural networks, k-nearest neighbour with one neighbours (kNN) and Linear Discriminant Analysis (LDA). The purpose of this comparison is to show that not all genes in a pathway contribute to a certain cellular process. The results of the experiment are shown in Table 2 . The texts in italic are the methods from the self-running experiment.
As shown in Table 2 , In comparing the gSVM-SCAD with L 1 -SVM and SVM-SCAD, it is interesting to note that the gSVM-SCAD outperforms the other two penalised classifiers in all three datasets with gSVM-SCAD is 18.63% higher than L 1 -SVM for lung cancer dataset, 6.57% higher in gender dataset and 8.75% higher in canine dataset. This is due to the SCAD as a non-convex penalty function is more robust to biasness when dealing with a large number of coefficients β in selecting informative genes compared to the L 1 penalty function (Fan and Li, 2001) . Therefore, the proposed method with SCAD penalty function selected more informatively genes within a pathway than the LASSO penalty. Table 2 further shows that the gSVM-SCAD had better results than the SVM-SCAD, with 20.27%, 9.37% and 7.41% higher in lung cancer, gender and canine datasets, respectively. It is demonstrated that group tuning parameters in the gSVM-SCAD provided flexibility in determining the λ for each pathway compared to the use of a general λ for whole pathways. This is because usually the genes within pathway have a different prior distribution. In order to show that not all genes in a pathway contributed to the development of specific cellular processes, the gSVM-SCAD is compared with four classifiers. The results are also shown in Table 2 . For the lung cancer dataset, it shows that the gSVM-SCAD outperformed all the classifiers, with 2.77% higher than PathwayRF, 3.38% higher than neural networks, 10.53% higher than LDA and lastly 12.04% higher than kNN. For the canine dataset, the gSVM-SCAD performed better than other classifiers except with PathwayRF and neural networks, with 0.8% higher than kNN with one and three neighbours, 4.46% higher than LDA, unfortunately lower with 4.84% and 1.25% than PathwayRF and neural networks, respectively. While for the gender dataset, the gSVM-SCAD obtained 5.58% higher than PathwayRF, 5.79% higher than neural networks, 4.89% higher than kNN one neighbour and 11.52% higher than LDA.
From the results in Table 2 , the gSVM-SCAD shows a better performance when compared to almost four classifiers for all three datasets. This is because the standard classifiers built a classification model using all genes within pathways. If there are uninformative genes inside the pathways, it reduced the classification performance. In contrast, the gSVM-SCAD does not include all genes in the pathways into the development of a classification model, as not all genes in a pathway contribute to cellular processes, due to the quality of pathway data as discussed by Chen et al. (2008) .
Biological validation
The gSVM-SCAD has been tested using the lung cancer dataset that has two possible output classes: tumour and normal. The selected genes and the top five pathways presented in Table 3 . For the lung cancer dataset, we used HLungDB (Wang et al., 2010) and genecards version 3.06 (www.genecards.org) to facilitate in validating the selected genes within pathways.
For the WNT signalling pathway, Mazieres et al. (2005) reported that the pathway plays a significant role in the development of lung and other colorectal cancers. From 24 genes inside the pathways, 16 genes selected by the gSVM-SCAD where twelve genes such as APC, HNF1A, CREBBP, HDAC1, MYC and CTNNB1, GSK3B, WNT1, CSNK1A1, CSNK2A1, TLE1 and AXIN1 are related to the lung cancer development while other remaining genes are not contributing to the lung cancer. With respect to the second pathway, it also contributes to the development of lung cancer, since the AKAP95 protein plays an important role in cell mitosis (Collas et al., 1999) , the gSVM-SCAD identifies seven out of ten genes included in the pathway with four genes such as DDX5, PRKACB, CDK1 and CCNB1 playing an important role in lung cancer development, while others have no evidence in lung cancer development. Table 3 Selected genes from the top five pathways in the lung cancer dataset
Pathways
No. of genes Selected gene(s)
WNT signalling pathway 24
APC (Mazieres et al., 2005) , HNF1A (Lanzafame et al., 2006) , CREBBP (Tillinghast et al., 2003) , HDAC1 (Sasaki et al., 2004) , MYC (Mazieres et al., 2005) , WNT1 (Huang et al., 2008) , CSNK1A1 (Zheng et al., 2007) , AXIN1 (Mazieres et al., 2005) , CSNK2A1 (Battacharjee et al., 2001) , CTNNB1 (Mazieres et al., 2005) , GSK3B (Mazieres et al., 2005) , TLE1 (Jagdis et al., 2009 ) PPARD, PPP2CA, TAB1, DVL1 AKAP95 role in mitosis and chromosome dynamics 10 DDX5 (Su et al., 2007) , PRKACB (Battacharjee et al., 2001) , CDK1 (Hsu et al., 2008) , CCNB1 (Kosacka et al., 2010) PPP2CA, PRKAR2B, PRKAR2A
Induction of apoptosis 36
FADD (Bhojani et al., 2005) , TNFSF10 (Sun et al., 2004) , CASP7 (Lee et al., 2010) , BCL2 (Nhung et al., 1999) , BIRC3 (Ekedahl et al., 2002) , CASP9 (Lee et al., 2010) , TRAF (Li et al., 2002) , BIRC (Kang et al., 2008) , CASP8 (Lee et al., 2010) , CASP3 ( Lee et al., 2010) , TNFRSF25 (Anglim et al., 2008) , CASP10 (Lee et al., 2010) , RARA (Wan et al., 2001) , CASP6 (Lee et al., 2010) TRADD, RELA, DFFA, RIPK1 Tyrosine metabolism 45
AOC3 (Battacharjee et al., 2001) , DDC (Vos et al., 1996) , ADH1C (Freudenheim et al., 2003) , GHR (Cao et al., 2008) , TPO (Werynska et al., 2003) , NAT6 (Battacharjee et al., 2001) , ALDH3A1 (Muzio et al., 2006) , ADH7 (Battacharjee et al., 2001) , MAOA (Battacharjee et al., 2001) , MAOB (Battacharjee et al., 2001) ADH5, PNMT, TAT, ARD1A, DBT, AOC2, ALDH1A3, AOX1, PRMT2, FAH, ALDH3B2, KAT2A, ADH6, ADH4, GOT2
Activation of Csk 30
PRKACB (Battacharjee et al., 2001) , CREBBP (Tillinghast et al., 2003) , HLA-DQB1 (Battacharjee et al., 2001) CD247, IL23A, PRKAR1B, GNGT1, CD3D, CD3E
Notes: The genes in italic text are uninformative genes.
The genes in bold text are genes that directly related to the lung cancer.
The gSVM-SCAD identifies that induction of apoptosis pathway as one of the lung cancer related pathway, where this pathway has been reported by Lee et al. (2010) as one of the contributor to the lung cancer development. Thirteen out of eighteen genes in the induction of apoptosis have been identified by the gSVM-SCAD as the significant genes, with thirteen genes being related to the lung cancer such as FADD, CASP3, CASP7, CASP8, CASP9, TNFSF10, BCL2, BIRC3, BIRC, TRAF, TNFRSF25, CASP10 and RARA. For the Tyrosine metabolism pathway, there are no references showing that this pathway is related to the lung cancer development. However, the gSVM-SCAD has identified several genes within this pathway that play an important role in the development of lung cancer, such as AOC3, DDC, GHR, TPO, NAT6, ALDH3A1, ADH7, MAOA, MAOB and ADH1C. This makes it possible that this pathway may relate to the development of lung cancer and thus prompting biologists to conduct further research on this pathway. While for the Activation of Csk pathway, Masaki et al. (2003) have reported that the activation of this pathway plays an important role in the development of lung cancer, with three genes marked as lung cancer genes.
For the canine experiment, we used 441 pathways whose sizes of genes vary between three and 151. The canine dataset has two possible output classes: cardiovascular injury dog and control dog classes. To obtain the gene id for this dataset, this research uses BLAST (Altschul et al., 1990) , where BLAST comparing the putative canine protein sequences with sequences of homologous human proteins in GeneBank (Benson et al., 2011) . For validation, the top five identified pathways were validated by the biological literature papers, especially from Pang et al. (2006) and the cardiovascular ontology website (http://www.geneontology.org/GO.cardio.shtml). This analysis yields biological relevant results.
As shown in Table 4 , the five most significant pathways in the canine dataset are: (a) TGF-beta signaling pathway; (b) Granzyme A mediated apoptosis pathway; (c) CD40L signalling pathway; (d) Antisense pathway and (e) Cycling of Ran in nucleocytoplasmic transport pathway. For the first pathway, Ruiz-Ortega et al. (2007) reported that the TGFbeta participates in the pathogenesis of multiple cardiovascular diseases. The gSVM-SCAD has identified four important genes in cardiovascular diseases such as RHOA, BMP4, Sp1 and ID2B. For the Granzyme A mediated apoptosis and Aminoacyl-tRNA biosynthesis pathway, Pang et al. (2006) have reported that they are significantly related to the phenotypes of interests. For the Granzyme A mediated apoptosis pathway, the gSVM-SCAD identified the two informative genes such as APEX1 and DFFB, while for the Aminoacyl-tRNA biosynthesis pathway all the genes selected were identified as informative genes. For the Antisense pathway, Pang et al. (2006) reported that three genes contain in this pathway and play an important role in the lesion score. The genes are ADAR, SFPQ and MATR3 where all the three genes are also identified and selected by the gSVM-SCAD. For the Cycling of Ran in the nucleocytoplasmic transport pathway, there is no event evidence that this pathway contributes to cardiovascular development or injury, but there are certain genes selected by the gSVM-SCAD that related to the apoptosis, such as RAN and RanBP1. For the gender dataset, we used 480 pathways. For this dataset, we were looking the genes within pathways that existed in the lymphoblastoid cell lines for both male and female (Pang et al., 2006) . The top five pathways with highest tenfold CV accuracy are shown in Table 5 . Our gSVM-SCAD had selected 11 genes out of total 726 genes within top five pathways. From the 11 genes, eight genes are proved to be related in lymphoblastoid cell lines for both male and female gender. Table 5 Selected genes from the top five pathways in the gender dataset
Pathways
No. of genes Selected gene(s)
Testis genes from xhx and netaffx 111 RPS4Y1 (Johnston et al., 2008) GNF female genes 116 XIST (Brown et al., 1991)
RAP down 434 DDX3X (Johnston et al., 2008) , NDUFS3 (Zhu et al., 2009 ), HDHD1A (Johnston et al., 2008) XINACT 34 RSP4X, DDX3X (Johnston et al., 2008) , PRKX (Johnston et al., 2008) Willard inact 31 RPS4X, STS (Johnston et al., 2008 ) RPS4P17
Notes: The genes in bold text are related to lymphoblastoid cell lines.
The genes in italic text are uninformative genes.
Conclusion
This paper focuses to identify the significant genes and pathways that relate to phenotypes of interests by proposing the gSVM-SCAD. From the experiments and analyses, the gSVM-SCAD is shown to outperform the other ML methods in almost all three datasets. In comparison of penalty functions, gSVM-SCAD has shown its superiority in selecting the informative genes within pathways compare to L 1 SVM. By providing group-specific tuning parameters, gSVM-SCAD had shown a better performance compare to an SVM-SCAD that provides a general penalty term for all pathways. The gSVM-SCAD also had shown its ability in identifying the significant genes and pathways where four pathways for lung cancer dataset and all five pathways in canine dataset are validated as biologically related to the phenotypes of interests, while majority of the selected genes from three datasets are proved as biologically relevance. Despite correctly selected genes and pathways, the gSVM-SCAD still selects the uninformative genes within pathways. This problem can lead to a low of discriminative performance as shown in Table 2 , where the gSVM-SCAD shows a lower accuracy than PathwayRF and the neural networks in the canine dataset. This is probably due to the improper selection of tuning parameter by the GACV. This is because SCAD penalty is a parametric method that relies on the parameter λ to balance the trade-off between data fitting and model parsimony (Zhang et al., 2006) . When the λ is too small, it can lead to the overfitting of the training model and give too little sparse to the produced classifier; and if λ is too big, it can lead to the underfitting to the training model, which again can give very sparse to the classifier (Zhang et al., 2006) . Therefore, further research especially in tuning parameter selection methods is needed in order to surmount the limitation in gSVM-SCAD.
